TEMBEXA (Brincidofovir) Patent Expiration, LOE Window & CMS Spending

TEMBEXA (Brincidofovir) by Emergent Biodefense Operations Lansing: FDA Orange Book core substance LOE 2034-07-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEmergent Biodefense Operations Lansing
FDA Application & PathwayN214460 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-07-30
Last Listed Patent or Exclusivity Date2034-07-30
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel